Perrigo acquires U.K. firm Galpharm
This article was originally published in The Tan Sheet
Executive Summary
The Allegan, Mich.-based private labeler announces Jan. 9 the $86 million acquisition of Galpharm Healthcare Ltd, an OTC store-brand drug supplier based in Yorkshire, U.K. Perrigo says it anticipates adding $55 million to its sales annually. The acquisition "further expands our global presence" and "complements our existing U.K. business," Perrigo Chairman and CEO Joseph Papa says in a release...
You may also be interested in...
Perrigo U.K. Trades Supplements Business In For Additional OTC Operations
Perrigo U.K. is getting out of the supplement business and adding to its OTC portfolio with a recent reverse agreement with NeutraHealth
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.